Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; 6 of the 20 sources its claims cite were checked for support.

Global Consensus Position Statement on the Use of Testosterone Therapy for Women

Open access

Abstract

This Position Statement has been endorsed by the International Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The International Society for Sexual Medicine...

Overview

CoChat Summary

TL;DR

This global consensus position statement concludes that the only evidence-based indication for testosterone therapy in women is treatment of postmenopausal women with hypoactive sexual desire disorder (HSDD) after formal biopsychosocial assessment. It finds insufficient evidence for testosterone use for any other symptom, condition, or disease prevention, and recommends only formulations achieving premenopausal physiologic testosterone concentrations with monitoring.

Key findings

  • The only evidence-based indication is HSDD in postmenopausal women; meta-analyses show a beneficial effect on sexual function including an average of one satisfying sexual event per month and increases in sexual desire, arousal, orgasmic function, pleasure, and sexual responsiveness, with reduced sexual concerns/distress (Level I, Grade A). There are insufficient data for premenopausal women or for any other outcome.
  • No effect was found on general wellbeing (Level I, Grade A), depressed mood (Level I, Grade B), bone mineral density at the spine, total hip, or femoral neck at 12 months (Level I, Grade A), or lean body mass, total body fat, or muscle strength (Level I, Grade A); evidence is insufficient for cognitive performance.
  • Safety findings: mild increases in acne and body/facial hair growth but not alopecia, clitoromegaly, or voice change (Level I, Grade A); oral testosterone adversely affects HDL- and LDL-cholesterol and is not recommended; non-oral short-term therapy shows no significant adverse lipid effects; no increases in blood pressure, blood glucose, or HbA1c; a non-significant trend for increased VTE; no serious adverse events, but safety data are not available beyond 24 months.
  • Breast findings: testosterone does not increase mammographic breast density; short-term transdermal testosterone does not impact breast cancer risk; data are insufficient for long-term breast cancer risk or prevention. Systemic DHEA is not recommended for HSDD.

Methods

  • A Task Force of representatives from leading societies conducted a systematic review and meta-analysis of the benefits and risks of testosterone therapy for women, then met on 17 May 2019 in Berlin, Germany, and drafted this consensus position statement.
  • Recommendations regarding benefits and risks are based on blinded placebo/comparator RCTs of at least 12 weeks’ duration included in meta-analyses; findings are reported with Levels of Evidence and Grades of Recommendation, and clinical practice recommendations are agreed expert opinions reached by unanimous consensus.

Limitations

  • The paper states insufficient data for premenopausal women; recommendations cannot be generalized to other FSD subtypes or women without sexual dysfunction; and they do not apply to injectables, pellets, formulations producing supraphysiological testosterone concentrations, or compounded preparations.
  • The paper states RCTs excluded women at high cardiometabolic disease risk, most included women taking concurrent estrogen therapy, and all were of relatively short duration; safety data for physiologic doses are not available beyond 24 months; long-term breast cancer risk and effects on myocardial infarction or death are insufficient.
  • The paper states few musculoskeletal studies, small participant numbers, all participants on concurrent estrogen, and none in women with osteoporosis; also evident from the text, many recommendations are Expert Opinion rather than RCT-based, and no approved female testosterone product exists, requiring off-label use of male formulations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/13697137.2019.1637079

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
From the PDF

Verification

Claims the paper makes

5 Valid · 6 Not valid · 7 Not checked · 36 Own results and interpretations

35 more claims

Create a free account to see all 54 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 7
  • Probably not a substantial claim. 10

Create a free account to see these claims.

Citations

Cites

Show all 18 references

Research works printed but not linked: 1

  1. Shekelle PG, 1999, West J Med, 170, 348

Cited by

See all 113

Metadata

Authors
Davis, S. R., Baber, R., Panay, N., Bitzer, J., Cerdas Perez, S., Islam, R. M., Kaunitz, A. M., Kingsberg, S. A., Lambrinoudaki, I., Liu, J., Parish, S. J., Pinkerton, J., Rymer, J., Simon, J. A., Vignozzi, L., & Wierman, M. E.
Affiliations
  • Monash University (AU)
  • University of Sydney, Sydney, Australia;
  • Queen Charlotte's and Chelsea Hospital (GB)
  • International AIDS Society (CH)
  • Endocrinology Department, Hospital Cima and University of Costa Rica, San José, Costa Rica;
  • University of Florida (US)
  • University Hospitals of Cleveland (US)
  • National and Kapodistrian University of Athens (GR)
  • Weill Cornell Medicine (US)
  • University of Virginia Health System (US)
  • Royal College of Obstetricians and Gynaecologists (GB)
  • George Washington University (US)
  • Endocrine Society (US)
Corresponding author
Davis, Susan R.
Venue
Climacteric
Published
2019-09-02
Volume
22
Issue
5
Pages
429-434
ISSN
  • 1369-7137 (ISSN-L)
  • 1473-0804
OpenAlex
W2971483732
Cited by
113
References
18
Citations by year
2026: 11 · 2025: 27 · 2024: 17 · 2023: 15 · 2022: 9 · 2021: 20 · 2020: 14
FWCI
6.23
Type
journal article
Language
en
Open access
Locations
  • Climacteric (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Monash University Research Portal (Monash University) (acceptedVersion, cc-by-nc-nd)
  • Florence Research (University of Florence) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
Keywords
testosterone replacement therapy, women, menopause, andropause, hormone replacement therapy, consensus statement, Endocrine Society
MeSH terms
Female, Humans, Societies, Medical, Testosterone, Global Health, Randomized Controlled Trials as Topic, Women's Health, Hormone Replacement Therapy, Consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global Consensus Position Statement on the Use of Testosterone Therapy for Women. https://app.cochat.ai/papers/10.1080/13697137.2019.1637079
The paper
Davis, S. R., Baber, R., Panay, N., Bitzer, J., Cerdas Perez, S., Islam, R. M., Kaunitz, A. M., Kingsberg, S. A., Lambrinoudaki, I., Liu, J., Parish, S. J., Pinkerton, J., Rymer, J., Simon, J. A., Vignozzi, L., & Wierman, M. E. (2019). Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric. https://doi.org/10.1080/13697137.2019.1637079

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.